Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-line PARP inhibition in ovarian cancer - standard of care for all?

Nature reviews. Clinical oncology - 1 Mar 2020

Banerjee Susana N, Lord Christopher J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to BRCA1 Protein
Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Progression-Free Survival

Source

Identifiers

PMID: 32051558
DOI: 10.1038/s41571-020-0335-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-line PARP inhibition in ovarian cancer - standard of care for all?PMID 32051558Read ↗

Making the best of PARP inhibitors in ovarian cancerSemantic proximity Read ↗

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsSemantic proximity Read ↗

PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP Inhibition in Cancer: An Update on Clinical DevelopmentSemantic proximity Read ↗

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.Semantic proximity Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.Semantic proximity Read ↗

Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.Semantic proximity Read ↗

New Therapies for Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.